Nanoviricides Inc (NNVC)
1.78
-0.07
(-3.78%)
USD |
NYAM |
Jul 02, 16:00
1.79
+0.01
(+0.56%)
After-Hours: 20:00
Nanoviricides SG&A Expense (TTM): 2.633M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 2.633M |
December 31, 2023 | 2.554M |
September 30, 2023 | 2.606M |
June 30, 2023 | 2.551M |
March 31, 2023 | 2.409M |
December 31, 2022 | 2.327M |
September 30, 2022 | 2.323M |
June 30, 2022 | 2.329M |
March 31, 2022 | 2.198M |
December 31, 2021 | 2.308M |
September 30, 2021 | 2.448M |
June 30, 2021 | 2.630M |
March 31, 2021 | 2.904M |
December 31, 2020 | 3.669M |
September 30, 2020 | 3.493M |
June 30, 2020 | 3.301M |
March 31, 2020 | 3.118M |
December 31, 2019 | 2.482M |
September 30, 2019 | 2.571M |
June 30, 2019 | 2.693M |
March 31, 2019 | 2.863M |
December 31, 2018 | 3.218M |
September 30, 2018 | 3.260M |
June 30, 2018 | 3.411M |
March 31, 2018 | 2.613M |
Date | Value |
---|---|
December 31, 2017 | 2.542M |
September 30, 2017 | 2.825M |
June 30, 2017 | 3.035M |
March 31, 2017 | 3.976M |
December 31, 2016 | 3.900M |
September 30, 2016 | 3.801M |
June 30, 2016 | 3.756M |
March 31, 2016 | 4.078M |
December 31, 2015 | 3.674M |
September 30, 2015 | 3.523M |
June 30, 2015 | 3.456M |
March 31, 2015 | 3.832M |
December 31, 2014 | 3.864M |
September 30, 2014 | 3.697M |
June 30, 2014 | 3.536M |
March 31, 2014 | 2.492M |
December 31, 2013 | 2.716M |
September 30, 2013 | 2.628M |
June 30, 2013 | 2.295M |
March 31, 2013 | 2.28M |
December 31, 2012 | 1.943M |
September 30, 2012 | 1.735M |
June 30, 2012 | 1.802M |
March 31, 2012 | 1.941M |
December 31, 2011 | 2.310M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
2.198M
Minimum
Mar 2022
3.669M
Maximum
Dec 2020
2.676M
Average
2.554M
Median
Dec 2023
SG&A Expense (TTM) Benchmarks
EyePoint Pharmaceuticals Inc | 50.92M |
Enanta Pharmaceuticals Inc | 57.17M |
GlycoMimetics Inc | 18.78M |
FibroGen Inc | 103.80M |
Corvus Pharmaceuticals Inc | 7.079M |